These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
44. Impact of radiotherapy and sequencing of systemic therapy on survival outcomes in melanoma patients with previously untreated brain metastasis: a multicenter DeCOG study on 450 patients from the prospective skin cancer registry ADOREG. Franklin C; Mohr P; Bluhm L; Grimmelmann I; Gutzmer R; Meier F; Garzarolli M; Weichenthal M; Pfoehler C; Herbst R; Terheyden P; Utikal J; Ulrich J; Debus D; Haferkamp S; Kaatz M; Forschner A; Leiter U; Nashan D; Kreuter A; Sachse M; Welzel J; Heinzerling L; Meiss F; Weishaupt C; Gambichler T; Weyandt G; Dippel E; Schatton K; Celik E; Trommer M; Helfrich I; Roesch A; Zimmer L; Livingstone E; Schadendorf D; Horn S; Ugurel S J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35688555 [TBL] [Abstract][Full Text] [Related]
45. Melanoma brain metastases that progress on BRAF-MEK inhibitors demonstrate resistance to ipilimumab-nivolumab that is associated with the Innate PD-1 Resistance Signature (IPRES). Lau PKH; Feran B; Smith L; Lasocki A; Molania R; Smith K; Weppler A; Angel C; Kee D; Bhave P; Lee B; Young RJ; Iravani A; Yeang HA; Vergara IA; Kok D; Drummond K; Neeson PJ; Sheppard KE; Papenfuss T; Solomon BJ; Sandhu S; McArthur GA J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34625515 [TBL] [Abstract][Full Text] [Related]
46. First-line pembrolizumab versus dabrafenib/trametinib treatment for BRAF V600-mutant advanced melanoma. Kim CG; Kim M; Hwang J; Kim ST; Jung M; Kim KH; Kim KH; Chang JS; Koom WS; Roh MR; Chung KY; Kim TM; Kim SK; Lee J; Shin SJ J Am Acad Dermatol; 2022 Nov; 87(5):989-996. PubMed ID: 36068115 [TBL] [Abstract][Full Text] [Related]
47. Survival of patients with advanced metastatic melanoma: The impact of MAP kinase pathway inhibition and immune checkpoint inhibition - Update 2019. Ugurel S; Röhmel J; Ascierto PA; Becker JC; Flaherty KT; Grob JJ; Hauschild A; Larkin J; Livingstone E; Long GV; Lorigan P; McArthur GA; Ribas A; Robert C; Zimmer L; Schadendorf D; Garbe C Eur J Cancer; 2020 May; 130():126-138. PubMed ID: 32179447 [TBL] [Abstract][Full Text] [Related]
48. Clinical Development of BRAF plus MEK Inhibitor Combinations. Subbiah V; Baik C; Kirkwood JM Trends Cancer; 2020 Sep; 6(9):797-810. PubMed ID: 32540454 [TBL] [Abstract][Full Text] [Related]
49. Real-world outcomes using PD-1 antibodies and BRAF + MEK inhibitors for adjuvant melanoma treatment from 39 skin cancer centers in Germany, Austria and Switzerland. Schumann K; Mauch C; Klespe KC; Loquai C; Nikfarjam U; Schlaak M; Akçetin L; Kölblinger P; Hoellwerth M; Meissner M; Mengi G; Braun AD; Mengoni M; Dummer R; Mangana J; Sindrilaru MA; Radmann D; Hafner C; Freund J; Rappersberger K; Weihsengruber F; Meiss F; Reinhardt L; Meier F; Rainer B; Richtig E; Ressler JM; Höller C; Eigentler T; Amaral T; Peitsch WK; Hillen U; Harth W; Ziller F; Schatton K; Gambichler T; Susok L; Maul LV; Läubli H; Debus D; Weishaupt C; Börger S; Sievers K; Haferkamp S; Zenderowski V; Nguyen VA; Wanner M; Gutzmer R; Terheyden P; Kähler K; Emmert S; Thiem A; Sachse M; Gercken-Riedel S; Kaune KM; Thoms KM; Heinzerling L; Heppt MV; Tratzmiller S; Hoetzenecker W; Öllinger A; Steiner A; Peinhaupt T; Podda M; Schmid S; Wollina U; Biedermann T; Posch C J Eur Acad Dermatol Venereol; 2023 May; 37(5):894-906. PubMed ID: 36433688 [TBL] [Abstract][Full Text] [Related]
50. Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma. Robert C; Grob JJ; Stroyakovskiy D; Karaszewska B; Hauschild A; Levchenko E; Chiarion Sileni V; Schachter J; Garbe C; Bondarenko I; Gogas H; Mandalá M; Haanen JBAG; Lebbé C; Mackiewicz A; Rutkowski P; Nathan PD; Ribas A; Davies MA; Flaherty KT; Burgess P; Tan M; Gasal E; Voi M; Schadendorf D; Long GV N Engl J Med; 2019 Aug; 381(7):626-636. PubMed ID: 31166680 [TBL] [Abstract][Full Text] [Related]
51. MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition. Wagle N; Van Allen EM; Treacy DJ; Frederick DT; Cooper ZA; Taylor-Weiner A; Rosenberg M; Goetz EM; Sullivan RJ; Farlow DN; Friedrich DC; Anderka K; Perrin D; Johannessen CM; McKenna A; Cibulskis K; Kryukov G; Hodis E; Lawrence DP; Fisher S; Getz G; Gabriel SB; Carter SL; Flaherty KT; Wargo JA; Garraway LA Cancer Discov; 2014 Jan; 4(1):61-8. PubMed ID: 24265154 [TBL] [Abstract][Full Text] [Related]
52. A matching-adjusted indirect comparison of combination nivolumab plus ipilimumab with BRAF plus MEK inhibitors for the treatment of BRAF-mutant advanced melanoma Tarhini AA; Toor K; Chan K; McDermott DF; Mohr P; Larkin J; Hodi FS; Lee CH; Rizzo JI; Johnson H; Moshyk A; Rao S; Kotapati S; Atkins MB ESMO Open; 2021 Apr; 6(2):100050. PubMed ID: 33556898 [TBL] [Abstract][Full Text] [Related]
53. Cutaneous Toxic Effects of BRAF Inhibitors Alone and in Combination With MEK Inhibitors for Metastatic Melanoma. Carlos G; Anforth R; Clements A; Menzies AM; Carlino MS; Chou S; Fernandez-Peñas P JAMA Dermatol; 2015 Oct; 151(10):1103-9. PubMed ID: 26200476 [TBL] [Abstract][Full Text] [Related]
56. Efficiency and tolerance of second-line triple BRAF inhibitor/MEK inhibitor/anti-PD1 combined therapy in BRAF mutated melanoma patients with central nervous system metastases occurring during first-line combined targeted therapy: a real-life survey. Fabre M; Lamoureux A; Meunier L; Samaran Q; Lesage C; Girard C; Du Thanh A; Moulis L; Dereure O Melanoma Res; 2024 Jun; 34(3):241-247. PubMed ID: 38546723 [TBL] [Abstract][Full Text] [Related]
57. Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma. Hamid O; Puzanov I; Dummer R; Schachter J; Daud A; Schadendorf D; Blank C; Cranmer LD; Robert C; Pavlick AC; Gonzalez R; Hodi FS; Ascierto PA; Salama AKS; Margolin KA; Gangadhar TC; Wei Z; Ebbinghaus S; Ibrahim N; Ribas A Eur J Cancer; 2017 Nov; 86():37-45. PubMed ID: 28961465 [TBL] [Abstract][Full Text] [Related]
58. Triplet combination of BRAF, MEK and PD-1/PD-L1 blockade in melanoma: the more the better? Trojaniello C; Vitale MG; Ascierto PA Curr Opin Oncol; 2021 Mar; 33(2):133-138. PubMed ID: 33399314 [TBL] [Abstract][Full Text] [Related]
59. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. Dummer R; Ascierto PA; Gogas HJ; Arance A; Mandala M; Liszkay G; Garbe C; Schadendorf D; Krajsova I; Gutzmer R; Chiarion-Sileni V; Dutriaux C; de Groot JWB; Yamazaki N; Loquai C; Moutouh-de Parseval LA; Pickard MD; Sandor V; Robert C; Flaherty KT Lancet Oncol; 2018 May; 19(5):603-615. PubMed ID: 29573941 [TBL] [Abstract][Full Text] [Related]
60. Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients. Sullivan RJ; Hamid O; Gonzalez R; Infante JR; Patel MR; Hodi FS; Lewis KD; Tawbi HA; Hernandez G; Wongchenko MJ; Chang Y; Roberts L; Ballinger M; Yan Y; Cha E; Hwu P Nat Med; 2019 Jun; 25(6):929-935. PubMed ID: 31171876 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]